
Orphalan SA today announced the expansion of the study into China, marking the formal randomisation of the first participant into the study globally. The study is an international, multicentre phase 3 clinical trial evaluating an investigational once-daily formulation of trientine tetrahydrochloride for the first-line treatment of Wilson disease.
The study evaluates the safety and efficacy of once-daily trientine tetrahydrochloride compared with D-penicillamine (DPA), an established copper-chelating therapy, over 48 weeks post randomisation.
The global study launched initially in the United States in August 2026 with a progressive activation of sites across the US and the King Faisal Specialist Hospital, Riyadh, Saudi Arabia. Additional sites expected to join this year as global enrolment expands to Pakistan.
This important milestone in China represents the first international study expansion in Wilson disease, with the study’s first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine.
Patient recruitment is now actively open across three leading Chinese hospital institutions, with Beijing Friendship Hospital serving as the coordinating lead site:
- Beijing Friendship Hospital, Capital Medical University (lead site)
- The Second Affiliated Hospital, Zhejiang University School of Medicine (site of the first randomised participant)
- Beijing You’an Hospital, Capital Medical University (activated clinical study site).


